Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations.

Blood - 23 Dec 2010

Pecci Alessandro, Gresele Paolo, Klersy Catherine, Savoia Anna, Noris Patrizia, Fierro Tiziana, Bozzi Valeria, Mezzasoma Anna Maria, Melazzini Federica, Balduini Carlo L

Abstract excerpt

Platelet transfusion is currently the primary medical treatment for reducing thrombocytopenia in patients with inherited thrombocytopenias. To evaluate whether stimulating megakaryopoiesis could increase platelet count in these conditions, we treated patients with a severe thrombocytopenia induced by MYH9 mutations (MYH9-related disease) with a nonpeptide thrombopoietin receptor agonist, eltrombopag. Twelve adult...

Topics

Join the communities discussing this publication.

Benzoates
Hydrazines
Molecular Motor Proteins
Platelet Aggregation
Platelet Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Receptors, Thrombopoietin

Thrombocytopenia

Source

Identifiers

PMID: 20844233
DOI: 10.1182/blood-2010-08-304725

Genes

MYH9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations.PMID 20844233Read ↗

Avatrombopag improves thrombocytopenia in MYH9-related disorder following eltrombopag treatment failure.Semantic proximity Read ↗

Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias.Semantic proximity Read ↗

Inherited thrombocytopenias: the evolving spectrum.Semantic proximity Read ↗

Clinic, pathogenic mechanisms and drug testing of two inherited thrombocytopenias, ANKRD26-related Thrombocytopenia and MYH9-related diseases.Semantic proximity Read ↗

Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation.Semantic proximity Read ↗

Role of Thrombopoietin Receptor Agonists in Inherited ThrombocytopeniaSemantic proximity Read ↗

MYH9-Related Platelet DisordersSemantic proximity Read ↗

Eltrombopag to Treat Thrombocytopenia During Last Month of Pregnancy in a Woman With MYH9-Related DiseaseSemantic proximity Read ↗

MYH9-related inherited thrombocytopenia: the genetic spectrum, underlying mechanisms, clinical phenotypes, diagnosis, and management approachesSemantic proximity Read ↗

MYH-9 Related Platelet Disorders: Strategies for Management and DiagnosisSemantic proximity Read ↗

It is not always immune thrombocytopenia: a case of MYH9-related platelet disorder caused by a novel mutation.Semantic proximity Read ↗

Thrombopoietin receptor agonists in hereditary thrombocytopenias.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.